Vol:.(1234567890)
Gastric Cancer (2021) 24:1100–1101 https://doi.org/10.1007/s10120-021-01205-5
1 3
CORRECTION
Correction to: Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation
Tomoko Jogo
1,2· Eiji Oki
1· Ryota Nakanishi
1· Koji Ando
1· Yuichiro Nakashima
3· Yasue Kimura
1· Hiroshi Saeki
4· Yoshinao Oda
2· Yoshihiko Maehara
5· Masaki Mori
1Published online: 5 July 2021
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2021
Correction to: Gastric Cancer
https:// doi. org/ 10. 1007/ s10120- 021- 01194-5
In the original publication of the article, the Figure 1 and Table 1 were published with errors. The corrected Fig. 1 and Table 1 is given in this correction.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original article can be found online at https:// doi. org/ 10. 1007/
s10120- 021- 01194-5.
* Eiji Oki
okieiji@surg2.med.kyushu-u.ac.jp
1 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
2 Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
3 Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
4 Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan
5 Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan
1101 Correction to: Expression of CD44 variant 9 induces chemoresistance of gastric cancer by…
1 3
Fig. 1 Flowchart depicting the patient selection process. This study included 596 primary GC patients who underwent surgery between January 2006 and December 2016. Among these patients, 193 GC patients were treated without preopera- tive chemotherapy from 2008 to 2012 and 29 GC patients received preoperative chemo- therapy from 2006 to 2016.
Among the 69 GC patients with pathological stage II–III without preoperative chemotherapy, 36 patients completed postop- erative adjuvant chemotherapy, 12 patients were treated with noncompleted postoperative adjuvant chemotherapy, and 21 patients did not receive postop- erative adjuvant chemotherapy.
GC gastric cancer, CD44v9 CD44 variant 9
Table 1 Association between CD44v9 expression in resected specimens and clinicopathological factors in GC patients who underwent surgery without preoperative therapy
Bold value indicates a significant difference
CD44v9 CD44 variant 9, GC gastric cancer, pStage pathological stage, GPx2 glutathione peroxidase 2
Factors CD44v9-negative
n = 142 (%) CD44v9-positive
n = 51 (%) p-value
Age (average ± SD) 64.2 ± 12.1 66 ± 11.5 0.3659
Sex Male 87 (61.3) 41 (80.4) 0.0154
Female 55 (38.7) 10 (19.6)
Differentiation Well/Moderately 67 (47.2) 27 (52.9) 0.5163
Poorly/Signet-ring cells 75 (52.8) 24 (47.1)
Depth of tumor invasion T1/2 103 (72.5) 26 (51.0) 0.0088
T3/4 39 (27.5) 25 (49.0)
Lymphatic permeation Absent 99 (69.7) 22 (43.1) 0.0012
Present 43 (30.3) 29 (56.9)
Vascular invasion Absent 117 (82.4) 35 (68.6) 0.0470
Present 25 (17.6) 16 (31.4)
Lymph node metastasis Absent 93 (65.5) 27 (53.0) 0.1309
Present 49 (34.5) 24 (47.0)
Distant metastasis Absent 139 (97.9) 45 (88.2) 0.0114
Present 3 (2.1) 6 (11.8)
pStage I/II 113 (79.6) 34 (66.7) 0.0839
III/IV 29 (20.4) 17 (33.3)
GPx2 expression Negative 85 (59.9) 12 (23.5) < 0.0001
Positive 57 (40.1) 39 (76.5)
